Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II

The University of Hong Kong (HKU)

Status and phase: Enrolling; Phase 4

Conditions: Exercise Physiology

Treatments: Drug: Placebo; Drug: Valsartan 80 mg

Study type: Interventional

Funder types: Other

Identifiers

NCT05269615

19200831

Details and patient eligibility

About

The major aims are to determine the effect of acute (single dose) blockade of ANGII receptor 1 (AT1) on the EPO response to a single session of endurance exercise, as well as determine the effect of chronic (8-week) blockade of AT1 on ET-induced adaptations in total circulating red blood volume and hemoglobin.

Full description

Physical activity, particularly when comprised of endurance training (ET) leading to cardiovascular adaptations, is considered the most effective intervention to augment life expectancy. Major health benefits induced by ET are closely associated (independently of traditional risk factors) with improvements in maximal oxygen consumption (VO2max), a hallmark of aerobic exercise capacity. The higher the VO2max the greater the likelihood to be free of cardiovascular disease, the main cause of mortality worldwide. Understanding the mechanisms explaining the improvement in VO2max with ET can provide sound basis for highly effective lifestyle and pharmacological interventions aimed to enhance cardiovascular health in the general population. So far, the essential role of ET-induced increased formation of red blood cells, i.e., erythropoiesis, has been firmly established for any improvement in VO2max. Yet, the underlying mechanism remains elusive. Clinical studies and recent investigations by the PI point towards the endocrine effects of key hormones that regulate blood volume (BV). Notably, the impact of ET-induced changes in angiotensin II (ANGII), a multifaceted hormone that modulates erythropoiesis through its effects on kidney erythropoietin (EPO) production, has to be experimentally elucidated in humans.

Enrollment: 80 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy status, absence of current medical symptoms or medication limiting incremental exercise testing
• No history of cardiac, pulmonary or kidney disease.

Exclusion criteria

• Individuals fulfilling the above criteria but currently involved in regular exercise training (> 5 hr/week)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

80 participants in 2 patient groups, including a placebo group

Valsartan tablets

Active Comparator group

Treatment:

Drug: Valsartan 80 mg

Placebo tablets

Placebo Comparator group

Treatment:

Drug: Placebo